An open-label, single-arm, Multicenter, prospective, phase 4, interventional, flexible dose study To evaluate the effectiveness of vortioxetine on goal achievement After a change in antidepressant medication for the treatment of Subjects with major depressive disorder
Can switching medications to Vortioxetine (brand name Trintellix) assist patients with depression to pursue personal goals?
Sponsor: Takeda
Enrolling: Male and Female Patients
Study Length: 12 Weeks
Clinic Visits: 5
IRB Number: 7513
U.S. Govt. ID: NCT02972632
Contact: Peter Arden: 646-774-8004 /
Additional Study Information: Patients who are either interested in discontinuing their current antidepressant or have discontinued an antidepressant in the past 6 weeks will be provided with an FDA approved medicine, Vortioxetine (brand name Trintellix). Treatment with Vortioxetine will start after the past antidepressant is discontinued. Vortioxetine dosage is adjustable throughout the study, and the optimal dose will be determined between the patient and the physician. The study is centered around whether Vortioxetine treatment is able to help patients pursue their self-determined goals over the course of the study.There is no placebo group and all study medication will be supplied at no cost.
This study is closed
David Hellerstein, MD
Do You Qualify?
Are you taking an antidepressant you want to discontinue or have you discontinued an antidepressant within the past 6 weeks? Yes No
Have you previously been on a mood stabilizer (for example, lithium/depakote) or an MAOI (for example, Parnate)? Yes No
Have you previously taken vortioxetine? Yes No
Have you take any psychostimulants (Concerta, Ritalin, Adderall, ect.) in the past 6 weeks?l Yes No
Are you currently pregnant or planning on becoming pregnant in the next 2 months? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Peter Arden